FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)

View source ↗

Summary

FDA approves a supplemental application for Sabril (vigabatrin) by Lundbeck Pharmaceuticals LLC, resulting in changes to the product's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Infantile Spasms

Drugs mentioned

• SABRIL (VIGABATRIN)

Snippet

SUPPL AP for SABRIL (VIGABATRIN)